The PD-1/PDL-1 inhibitors now forms part of first-line NSCLC mono-therapy treatments, or combined with chemotherapy or chemoradiotherapy in patients with stage III unresectable NSCLC (252). Here, PDCD1 is linked to non-small cell lung carcinoma.